GENFF (Genflow Biosciences) Common Stock: $0.20 Mil (As of Dec. 2025)


What is Genflow Biosciences Common Stock?

Genflow Biosciences GENFF Common Stock is $0.20 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Genflow Biosciences's quarterly common stock increased from Dec. 2024 ($0.13 Mil) to Jun. 2025 ($0.19 Mil) and increased from Jun. 2025 ($0.19 Mil) to Dec. 2025 ($0.20 Mil).

Genflow Biosciences's annual common stock increased from Dec. 2023 ($0.11 Mil) to Dec. 2024 ($0.13 Mil) and increased from Dec. 2024 ($0.13 Mil) to Dec. 2025 ($0.20 Mil).

Genflow Biosciences Common Stock Historical Data

* Premium members only.

The historical data trend for Genflow Biosciences's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genflow Biosciences Common Stock Chart

Genflow Biosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Common Stock
0.10 0.11 0.11 0.13 0.20

Genflow Biosciences Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.13 0.13 0.19 0.20

Genflow Biosciences Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.

Frequently Asked Questions Learn more about Common Stock →
What does a Common Stock of $0.20 Mil mean?
Genflow Biosciences (GENFF) has a Common Stock of $0.20 Mil as of Dec. 2025. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Genflow Biosciences and its competitors.
Is Genflow Biosciences' Common Stock too high?
Genflow Biosciences' current Common Stock is $0.20 Mil.
How does Genflow Biosciences' Common Stock compare to VRTX and REGN?
Genflow Biosciences' Common Stock of $0.20 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Common Stock for a Biotechnology company?
A good Common Stock depends on the Biotechnology industry context. However, Common Stock should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Common Stock mean?
A high Common Stock can signal that a stock is expensive relative to its fundamentals. Common Stock is the par value of a company's shares outstanding, as listed on the balance sheet. View historical data on Genflow Biosciences and its competitors. Genflow Biosciences's current Common Stock is $0.20 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genflow Biosciences stock overvalued right now?
Genflow Biosciences (GENFF) has a current Common Stock of $0.20 Mil. The current Common Stock is $0.20 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Common Stock calculated?
Common Stock is calculated from a company's financial statements. For Genflow Biosciences (GENFF), the current Common Stock is $0.20 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Genflow Biosciences Business Description

Other Exchanges GENF:UKWQ5:Germany
Address 6 Heddon Street, London, GBR, W1B 4BT
Genflow Biosciences PLC is a preclinical biotechnology company focused on the development of biological interventions (namely gene therapies) which are aimed at tackling the effects of aging, potentially slowing or halting the aging process and so reducing the incidence of age-related diseases and thereby increasing health span. Its flagship compound, GF-1002, is based on the delivery of a variant of the SIRT6 gene and is currently in preclinical development.